Algernon Pharmaceuticals (FRA:AGW0) COGS-to-Revenue : 0.00 (As of Nov. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals COGS-to-Revenue?

Algernon Pharmaceuticals's Cost of Goods Sold for the three months ended in Nov. 2024 was €0.00 Mil. Its Revenue for the three months ended in Nov. 2024 was €0.00 Mil.

Algernon Pharmaceuticals's COGS to Revenue for the three months ended in Nov. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Algernon Pharmaceuticals's Gross Margin % for the three months ended in Nov. 2024 was N/A%.

Algernon Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Algernon Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals COGS-to-Revenue Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Aug24

COGS-to-Revenue

Get a 7-Day Free Trial

Algernon Pharmaceuticals Quarterly Data
	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24
COGS-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Algernon Pharmaceuticals COGS-to-Revenue Calculation

Algernon Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Aug. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Algernon Pharmaceuticals's COGS to Revenue for the quarter that ended in Nov. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Algernon Pharmaceuticals (FRA:AGW0) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Algernon Pharmaceuticals's Gross Margin % for the three months ended in Nov. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Algernon Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (FRA:AGW0) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

AGNPF:USA AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis, and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals Headlines

No Headlines